26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
25 June 2020JPIAMR webinar series on antibiotic use and the risk for increased antibiotic resistance in the COVID-19 pandemicThe burden of AMR is likely to increase due to the escalated use of antibiotics to treat bacterial co-infections in…read more >>
25 June 2020tranScrip: COVID-19 Panel Discussion: Successful Medical Affairs in the “New Normal” after COVID-19During this hour-long panel discussion, we will hear from those embracing virtual medical affairs in a world with COVID-19.read more >>
25 June 2020tranScrip is delighted to announce that one of the trials they have been involved in running on COVID 19 has generated positive resultstranScrip is a specialist drug development and lifecycle management service provider based in the UK with small satellite offices in…read more >>
16 June 2020REVIVE Webinar: Bringing new treatments for drug-resistant infections to all who need themThe following topics will be presented: - Antibiotic resistance and the GARDP response - Tackling the growing threat of hospital…read more >>
09 June 2020REVIVE Webinar: Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinationsTopics discussed will include: - Understanding the inherent challenges associated with PK/PD of BL/BLI combinations - Demonstrating new approaches to…read more >>
04 June 2020Antimicrobial Resistance: The Requirement for a New Business Model for the Development, Production and Sales of New AntibioticsThe online event will look at the requirement for a new business model for the development, production and sales of…read more >>
19 May 2020REVIVE Webinar: Assay development for measuring antibiotic accumulation in Gram-negative bacteriaAssay development for measuring antibiotic accumulation in Gram-negative bacteriaread more >>
12 May 2020REVIVE Webinar: Probability of target attainment analyses for dose selection in antimicrobial drug developmentTopics discussed will include: - An overview of what is meant by the probability of target attainment (PTA) - How…read more >>
07 May 2020Webinar: Economics Behind the Commercialization of an AMR Product – Understanding the Issues and Fixing itThe goal of this webinar is to provide insight into the economic fundamentals and post marketing commitments, inventory build and…read more >>
